AACR Cancer Disparities Progress Report 2020


Book Description

Cancer health disparities are one of the most pressing public health challenges we face today in the United States, and the AACR Cancer Disparities Progress Report 2020 highlights areas of progress in addressing this challenge. It also emphasizes the need for continued research and for increased collaboration among stakeholders if we are to achieve the bold vision of health equity. Racial and ethnic minorities are among the populations groups that have long experienced significant cancer health disparities, although progress in the form of narrowing of the disparities in the overall cancer death rate among racial and ethnic groups in the United States is evident in recent years. We have also made progress in deepening our understanding of the many complex factors that contribute to cancer health disparities. Most important among these are social, clinical, behavioral, cultural, psychological, environmental, and genetic and biological factors. Unfortunately, as pointed out in the report, most data on cancer biology comes from white individuals and there is an urgent need for much more research to increase our understanding of the genes and mutations associated with cancer in racial and ethnic minorities.Despite recent advances in cancer treatment, racial and ethnic minorities are often less likely to receive the standard of care recommended for the type and stage of cancer with which they have been diagnosed. To achieve health equity for everyone, stakeholders must work together to remove the barriers that prevent all segments of the population benefiting equally from lifesaving progress in cancer treatment, including a serious lack of racial and ethnic diversity among those who pariticipate in cancer clinical trials. Over the past decade, the field of cancer health disparities research has evolved from simply describing different outcomes among populations into an established multidisciplinary field of research. To further accelerate the pace of progress against cancer health disparities concerted efforts by all stakeholders is absolutely critical. Thus, the report concludes with a call to action to Congress. Through robust and sustained funding, Congress help us achieve the bold vision of health equity.







The Philadelphia Chromosome: A Genetic Mystery, a Lethal Cancer, and the Improbable Invention of a Lifesaving Treatment


Book Description

One of The Wall Street Journal’s 10 Best Nonfiction Books of the Year Philadelphia, 1959: A scientist scrutinizing a single human cell under a microscope detects a missing piece of DNA. That scientist, David Hungerford, had no way of knowing that he had stumbled upon the starting point of modern cancer research— the Philadelphia chromosome. It would take doctors and researchers around the world more than three decades to unravel the implications of this landmark discovery. In 1990, the Philadelphia chromosome was recognized as the sole cause of a deadly blood cancer, chronic myeloid leukemia, or CML. Cancer research would never be the same. Science journalist Jessica Wapner reconstructs more than forty years of crucial breakthroughs, clearly explains the science behind them, and pays tribute—with extensive original reporting, including more than thirty-five interviews—to the dozens of researchers, doctors, and patients with a direct role in this inspirational story. Their curiosity and determination would ultimately lead to a lifesaving treatment unlike anything before it. The Philadelphia Chromosome chronicles the remarkable change of fortune for the more than 70,000 people worldwide who are diagnosed with CML each year. It is a celebration of a rare triumph in the battle against cancer and a blueprint for future research, as doctors and scientists race to uncover and treat the genetic roots of a wide range of cancers.







Implementation Science at a Glance


Book Description

While many effective interventions can reduce cancer risk, incidence, and death, as well as enhance quality of life, they are of no benefit if they cannot be delivered to those in need. In the face of increasingly dynamic and resource-constrained conditions, implementation science plays a critical role in delivering cancer control practices. This 30-page workbook was written by members of the NCI (National Cancer Institute) implementation Science team and reviewed by nearly 100 public health practitioners and implementation science researchers. Through summaries of key theories, methods, and models, the guide shows how greater use of implementation science can support the effective adoption of evidence-based interventions. Case studies illustrate how practitioners are successfully applying implementation science in their cancer control programs




The Drug Development Paradigm in Oncology


Book Description

Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.




Delivering High-Quality Cancer Care


Book Description

In the United States, approximately 14 million people have had cancer and more than 1.6 million new cases are diagnosed each year. However, more than a decade after the Institute of Medicine (IOM) first studied the quality of cancer care, the barriers to achieving excellent care for all cancer patients remain daunting. Care often is not patient-centered, many patients do not receive palliative care to manage their symptoms and side effects from treatment, and decisions about care often are not based on the latest scientific evidence. The cost of cancer care also is rising faster than many sectors of medicine--having increased to $125 billion in 2010 from $72 billion in 2004--and is projected to reach $173 billion by 2020. Rising costs are making cancer care less affordable for patients and their families and are creating disparities in patients' access to high-quality cancer care. There also are growing shortages of health professionals skilled in providing cancer care, and the number of adults age 65 and older--the group most susceptible to cancer--is expected to double by 2030, contributing to a 45 percent increase in the number of people developing cancer. The current care delivery system is poorly prepared to address the care needs of this population, which are complex due to altered physiology, functional and cognitive impairment, multiple coexisting diseases, increased side effects from treatment, and greater need for social support. Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis presents a conceptual framework for improving the quality of cancer care. This study proposes improvements to six interconnected components of care: (1) engaged patients; (2) an adequately staffed, trained, and coordinated workforce; (3) evidence-based care; (4) learning health care information technology (IT); (5) translation of evidence into clinical practice, quality measurement and performance improvement; and (6) accessible and affordable care. This report recommends changes across the board in these areas to improve the quality of care. Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis provides information for cancer care teams, patients and their families, researchers, quality metrics developers, and payers, as well as HHS, other federal agencies, and industry to reevaluate their current roles and responsibilities in cancer care and work together to develop a higher quality care delivery system. By working toward this shared goal, the cancer care community can improve the quality of life and outcomes for people facing a cancer diagnosis.




Physical Activity and Cancer


Book Description

This book explores in depth the relation between physical activity and cancer control, including primary prevention, coping with treatments, recovery after treatments, long-term survivorship, secondary prevention, and survival. The first part of the book presents the most recent research on the impact of physical activity in preventing a range of cancers. In the second part, the association between physical activity and cancer survivorship is addressed. The effects of physical activity on supportive care endpoints (e.g., quality of life, fatigue, physical functioning) and disease endpoints (e.g., biomarkers, recurrence, survival) are carefully analyzed. In addition, the determinants of physical activity in cancer survivors are discussed, and behavior change strategies for increasing physical activity in cancer survivors are appraised. The final part of the book is devoted to special topics, including the relation of physical activity to pediatric cancer survivorship and to palliative cancer care.




The Health Benefits of Smoking Cessation


Book Description